R
Robert Jambou
Researcher at National Institutes of Health
Publications - 8
Citations - 240
Robert Jambou is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Genetic enhancement & Genome editing. The author has an hindex of 6, co-authored 8 publications receiving 227 citations.
Papers
More filters
Journal ArticleDOI
Genome editing technologies: defining a path to clinic.
Jacqueline Corrigan-Curay,Marina O'Reilly,Donald B. Kohn,Paula M. Cannon,Gang Bao,Frederic D. Bushman,Dana Carroll,Toni Cathomen,J. Keith Joung,David Roth,Michel Sadelain,Andrew M. Scharenberg,Christof von Kalle,Feng Zhang,Robert Jambou,Eugene Rosenthal,Morad Hassani,Aparna Singh,Matthew H. Porteus +18 more
TL;DR: Recently developed genomic editing technologies have the potential to be powerful tools for gene therapy because of their ability to inactivate genes, correct mutated sequences, or insert intact genes While the genomic editing field is advancing at an exceptionally rapid pace, there remain key issues regarding development of appropriate preclinical assays to evaluate off-target effects and establish safety.
Journal ArticleDOI
T-cell immunotherapy: looking forward.
Jacqueline Corrigan-Curay,Hans-Peter Kiem,David Baltimore,Marina O'Reilly,Renier J. Brentjens,Laurence J.N. Cooper,Stephen J. Forman,Stephen Gottschalk,Philip D. Greenberg,Richard P. Junghans,Helen E. Heslop,Michael C. Jensen,Crystal L. Mackall,Carl H. June,Oliver W. Press,Daniel J. Powell,Antoni Ribas,Steven A. Rosenberg,Michel Sadelain,Brian G. Till,Amy P. Patterson,Robert Jambou,Eugene Rosenthal,Linda Gargiulo,Maureen Montgomery,Donald B. Kohn +25 more
TL;DR: The T Cell Immunotherapy: Optimizing T-cell trial design workshop as discussed by the authors was a workshop sponsored by the National Institutes of Health's Office of Biotechnology Activities (OBA), which brought together researchers to discuss the scientific advances and share new data on key trial design issues.
Journal ArticleDOI
Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy.
Jacqueline Corrigan-Curay,Odile Cohen-Haguenauer,Odile Cohen-Haguenauer,Marina O'Reilly,Susan R. Ross,Hung Fan,Naomi Rosenberg,Nikunj V. Somia,Nancy M. P. King,Theodore Friedmann,Cynthia E. Dunbar,Alessandro Aiuti,Luigi Naldini,Christopher Baum,Christof von Kalle,Hans-Peter Kiem,Eugenio Montini,Frederic D. Bushman,Brian P. Sorrentino,Manuel J.T. Carrondo,Harry L. Malech,Gösta Gahrton,Robyn S. Shapiro,Linda Wolff,Eugene Rosenthal,Robert Jambou,John A. Zaia,Donald B. Kohn +27 more
TL;DR: Recent reports of insertional mutagenesis leading to myelodysplastic syndrome in a trial for chronic granulomatous disease and a case of leukemia in a Trial for Wiskott-Aldrich syndrome, both of which used g-retroviral vectors, underscored that this type of toxicity can also apply to other disease settings.
Book ChapterDOI
NIH oversight of human gene transfer research involving retroviral, lentiviral, and adeno-associated virus vectors and the role of the NIH recombinant DNA advisory committee.
Marina O'Reilly,Allan C. Shipp,Eugene Rosenthal,Robert Jambou,Tom Shih,Maureen Montgomery,Linda Gargiulo,Amy P. Patterson,Jacqueline Corrigan-Curay +8 more
TL;DR: A transparent oversight system that extends to human gene transfer protocols that are either conducted with NIH funding or conducted at institutions that receive NIH funding for recombinant DNA research has fostered the development of retroviral, lentiviral, and adeno-associated viral vector mediated gene delivery.
Journal ArticleDOI
Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012.
Marina O'Reilly,Donald B. Kohn,Jeffrey S. Bartlett,Janet M. Benson,Philip J. Brooks,Barry J. Byrne,Carlos Camozzi,Kenneth Cornetta,Ronald G. Crystal,Yuman Fong,Linda Gargiulo,Rashmi Gopal-Srivastava,Katherine A. High,Samuel G. Jacobson,Robert Jambou,Maureen Montgomery,Eugene Rosenthal,R. Jude Samulski,Sonia I. Skarlatos,Brian P. Sorrentino,James M. Wilson,Yun Xie,Jacqueline Corrigan-Curay +22 more
TL;DR: The challenges and opportunities for advancing the field including means for enhancing data sharing for preclinical and clinical studies, development and utilization of available NIH resources, and interactions with the U.S. Food and Drug Administration are discussed.